We are live on ! Find out more
AVIR icon

Atea Pharmaceuticals
AVIR

115 hedge funds and large institutions have $154M invested in Atea Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 39 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 6

8% more funds holding

Funds holding: 106 → 115 (+9)

5.43% more ownership

Funds ownership: 61.57% → 66.99% (+5.4%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

15% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 39

19% less capital invested

Capital invested by funds: $190M → $154M (-$35.5M)

96% less call options, than puts

Call options by funds: $163K | Put options by funds: $3.67M

Holders
115
Holders Change
+9
Holders Change %
+8.49%
% of All Funds
1.51%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
15
Increased
33
Reduced
39
Closed
6
Calls
$163K
Puts
$3.67M
Net Calls
-$3.51M
Net Calls Change
-$3.52M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.07M
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$989K
3
Bank of America
Bank of America
North Carolina
+$696K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$577K
5
Group One Trading
Group One Trading
Illinois
+$478K

Top Sellers

Rank Fund Capital Flow
1
AC
Almitas Capital
California
-$1.6M
2
BlackRock
BlackRock
New York
-$715K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$608K
4
BCM
BML Capital Management
Indiana
-$464K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$392K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$910K +$696K +203,905 +186%
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$876K +$989K +289,647 +2,368%
Wellington Management Group
28
Wellington Management Group
Massachusetts
$762K -$330K -96,676 -27%
N
29
Nuveen
North Carolina
$742K – – –
Barclays
30
Barclays
United Kingdom
$700K -$69.4K -20,310 -8%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$602K +$25K +7,331 +4%
HSBC Holdings
32
HSBC Holdings
United Kingdom
$590K +$36.1K +10,577 +5%
Jane Street
33
Jane Street
New York
$557K +$416K +121,699 +173%
American Century Companies
34
American Century Companies
Missouri
$527K +$27K +7,895 +5%
AI
35
Auour Investments
Massachusetts
$513K – – –
EWA
36
EverSource Wealth Advisors
Alabama
$438K +$194K +56,954 +61%
Group One Trading
37
Group One Trading
Illinois
$418K +$478K +139,954 +3,308%
BCM
38
Bridgeway Capital Management
Texas
$415K – – –
AllianceBernstein
39
AllianceBernstein
Tennessee
$371K – – –
Invesco
40
Invesco
Georgia
$361K -$88.2K -25,818 -17%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$329K -$19.8K -5,808 -5%
SO
42
STRS Ohio
Ohio
$329K – – –
State of Wisconsin Investment Board
43
State of Wisconsin Investment Board
Wisconsin
$310K -$8.11K -2,374 -2%
UBS Group
44
UBS Group
Switzerland
$296K -$24.6K -7,213 -7%
T. Rowe Price Associates
45
T. Rowe Price Associates
Maryland
$283K +$60.2K +17,623 +22%
CSS
46
Cubist Systematic Strategies
Connecticut
$255K +$300K +87,774 New
Marshall Wace
47
Marshall Wace
United Kingdom
$252K +$212K +62,193 +250%
RC
48
Rangeley Capital
Connecticut
$232K +$92.2K +27,000 +51%
Los Angeles Capital Management
49
Los Angeles Capital Management
California
$224K +$148K +43,229 +127%
Macquarie Group
50
Macquarie Group
Australia
$203K – – –
1
2
3 4 5

AVIR Hedge Fund Activity: Q3 2025 in Review

115 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q3 2025, worth a combined $154M — down 19% from $190M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new AVIR positions and 6 closed out — a net gain of 9 holders — while 33 added to existing stakes and 39 trimmed.

The largest buyer was Millennium Management, adding an estimated $1.07M. The largest seller was Almitas Capital, exiting entirely with an estimated $1.6M sold.

  • 115 institutional investors held Atea Pharmaceuticals (AVIR) as of Q3 2025, up from 106 in Q2 2025.
  • Funds reported $154M of Atea Pharmaceuticals stock for Q3 2025, down 19% quarter-over-quarter.
  • 15 funds opened new Atea Pharmaceuticals positions in Q3 2025 and 6 closed out, a net change of +9 holders.
  • The largest Atea Pharmaceuticals buyer in Q3 2025 was Millennium Management, an estimated $1.07M added.
  • The largest Atea Pharmaceuticals seller in Q3 2025 was Almitas Capital, an estimated $1.6M sold.

Based on aggregated 13F filings for Q3 2025.